0 CHECKOUT

HIV-1 Infection - Pipeline Review, H1 2015

  • ID: 3215933
  • March 2015
  • 319 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AlphaVax, Inc.
  • Biosantech SA
  • FIT Biotech Oy
  • InnaVirVax SA
  • Oncovir, Inc.
  • TaiMed Biologics Inc.
  • MORE

HIV-1 Infection - Pipeline Review, H1 2015

Summary:

This, ‘HIV-1 Infection - Pipeline Review, H1 2015’, provides an overview of the HIV-1 Infection’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AlphaVax, Inc.
  • Biosantech SA
  • FIT Biotech Oy
  • InnaVirVax SA
  • Oncovir, Inc.
  • TaiMed Biologics Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
HIV-1 Infection Overview
Therapeutics Development
Pipeline Products for HIV-1 Infection - Overview
Pipeline Products for HIV-1 Infection - Comparative Analysis
HIV-1 Infection - Therapeutics under Development by Companies
HIV-1 Infection - Therapeutics under Investigation by Universities/Institutes
HIV-1 Infection - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
HIV-1 Infection - Products under Development by Companies
HIV-1 Infection - Products under Investigation by Universities/Institutes
HIV-1 Infection - Companies Involved in Therapeutics Development
AlphaVax, Inc.
AltraVax Inc.
Aphios Corporation
Argos Therapeutics, Inc.
Bionor Pharma ASA
Biosantech SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
CompleGen, Inc.
Critical Outcome Technologies Inc.
CytoDyn Inc.
Enzo Biochem, Inc.
FIT Biotech Oy
GeneCure LLC
Gilead Sciences, Inc.
GlaxoSmithKline plc
Heat Biologics, Inc.
InnaVirVax SA
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Merck & Co., Inc.
Mymetics Corporation
Myrexis, Inc.
Oncovir, Inc.
OyaGen Inc.
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
Pharis Biotec GmbH
Spider Biotech
TaiMed Biologics Inc.
Takara Bio Inc.
Theravectys S.A.
Tobira Therapeutics, Inc.
United Biomedical, Inc.
Valens Therapeutics, Inc.
Vichem Chemie Research Ltd.
ViiV Healthcare Limited
HIV-1 Infection - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(cenicriviroc mesylate + lamivudine + efavirenz) - Drug Profile
(cenicriviroc mesylate + lamivudine) - Drug Profile
(darunavir + cobicistat + emtricitabine + tenofovir alafenamide) - Drug Profile
(dolutegravir + rilpivirine) - Drug Profile
(elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide) - Drug Profile
(emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide) - Drug Profile
(emtricitabine + tenofovir alafenamide) - Drug Profile
(lamivudine + raltegravir potassium) - Drug Profile
1-E703 - Drug Profile
3B3-PE38 - Drug Profile
AGS-004 - Drug Profile
AH-0109 - Drug Profile
ALVAC-HIV vCP1521 + AIDSVAX B/B - Drug Profile
Antibodies to Inhibit gp120 for HIV-1 Infection - Drug Profile
Antisense Oligonucleotides to Inhibit GAG for HIV-1 Infection - Drug Profile
APH-0812 - Drug Profile
AVX-101 - Drug Profile
BMS-585248 - Drug Profile
BMS-955176 - Drug Profile
CCL-14 - Drug Profile
Cell Therapy for HIV-1 Infection - Drug Profile
censavudine - Drug Profile
CG-1 - Drug Profile
CGX-0471 - Drug Profile
CGX-1079 - Drug Profile
CPI-43132 - Drug Profile
Dendritic Cell Therapy for HIV-1 Infection - Drug Profile
doravirine - Drug Profile
Drug to Inhibit Reverse Transcriptase for HIV-1 - Drug Profile
Drugs to Antagonize P2X for HIV-1 Infection - Drug Profile
Drugs to Inhibit HIV-1 Protease for HIV-1 Infection - Drug Profile
Drugs to Inhibit Reverse Transcriptase for Viral Infections - Drug Profile
Drugs to Inhibit Vif Protein for HIV-1 Infection - Drug Profile
DS-001 - Drug Profile
DS-003 - Drug Profile
DS-007 - Drug Profile
F2 - Drug Profile
FIT-06 + LIPO-5 - Drug Profile
fostemsavir - Drug Profile
FP-1 - Drug Profile
Gene Therapy for HIV-1 Infection - Drug Profile
Gene Therapy to Activate MazF Gene for HIV-1 - Drug Profile
Gene Therapy to Inhibit Gag for HIV-1 Infection - Drug Profile
GRL-0519 - Drug Profile
GS-8374 - Drug Profile
GS-9883 - Drug Profile
GSK-732462 - Drug Profile
HGTV-43 - Drug Profile
HIV [serotype 5] vaccine - Drug Profile
HIV [type 1] vaccine - Drug Profile
HIV Vaccine - Drug Profile
HIV vaccine - Drug Profile
HIV vaccine - Drug Profile
HIV-1 vaccine - Drug Profile
HIV-1 vaccine - Drug Profile
HIV-1 vaccine - Drug Profile
HIV-1 vaccine - Drug Profile
HIV-1 vaccine - Drug Profile
HIV-1 vaccine - Drug Profile
HIV-1 vaccine - Drug Profile
HIV-1 vaccine - Drug Profile
HIV-1 vaccine - Drug Profile
HIV-1 vaccine - Drug Profile
HIV-1 vaccine (bivalent) - Drug Profile
HIV-1 vaccine 1 - Drug Profile
HIV-1 vaccine 1 - Drug Profile
HIV-1 vaccine 3 - Drug Profile
HIV-1 vaccine 4 - Drug Profile
HIV-1 vaccine 5 - Drug Profile
HIVAX - Drug Profile
HNG-156 - Drug Profile
HS-HIV1 - Drug Profile
HUM-8P.342 - Drug Profile
ibalizumab - Drug Profile
Leukothera - Drug Profile
M-48U1 - Drug Profile
MK-8507 - Drug Profile
MK-8591 - Drug Profile
MK-8970 - Drug Profile
MYMV-101 - Drug Profile
MYMV-201 - Drug Profile
NB-325 - Drug Profile
PENNVAX-B - Drug Profile
Peptides to Target TAR for HIV-1 Infection - Drug Profile
PF-46396 - Drug Profile
PGN-632 - Drug Profile
Poly-ICLC - Drug Profile
PRO-140 - Drug Profile
Protein for HIV-1 Infection - Drug Profile
Protein to Inhibit Tat and Rev for HIV-1 - Drug Profile
rAd5 Env A + rAd35 Env A Vaccine - Drug Profile
RC-100b - Drug Profile
Recombinant Enzyme for HIV-1 Infection - Drug Profile
Recombinant Peptide to Inhibit gp120 for HIV-1 - Drug Profile
Recombinant Peptides for HIV-1 Infection and Influenza A Infections - Drug Profile
Recombinant Protein to Target gp120 for HIV-1 Infection - Drug Profile
Recombinant Protein to Target gp120 for HIV-1 Infections - Drug Profile
rilpivirine - Drug Profile
RN-18 - Drug Profile
SB-105A10 - Drug Profile
Small Molecule for HIV-1 Infection - Drug Profile
Small Molecule for HIV-1 Infection - Drug Profile
Small Molecule to Inhibit Gag for HIV-1 Infection - Drug Profile
Small Molecule to Inhibit HIV-1 Protease for HIV-1 Infection - Drug Profile
Small Molecule to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection - Drug Profile
Small Molecule to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection - Drug Profile
Small Molecule to Inhibit Reverse Transcriptase for HIV-1 infection - Drug Profile
Small Molecule to Target Capsid Protein for HIV-1 Infection - Drug Profile
Small Molecule to Target Matrix Protein for HIV-1 Infection - Drug Profile
Small Molecules for HIV-1 Infection - Drug Profile
Small Molecules for HIV-1 Infection - Drug Profile
Small Molecules for HIV-1 Infection - Drug Profile
Small Molecules for HIV-1 Infection - Drug Profile
Small Molecules for HIV-1 Infection - Drug Profile
Small Molecules for HIV-1 Infections - Drug Profile
Small Molecules for HIV-1, Neurodegenerative Disorders and Type 2 Diabetes - Drug Profile
Small Molecules for Retroviral Infections - Drug Profile
Small Molecules to Inhibit CDK9 for HIV-1 Infection - Drug Profile
Small Molecules to Inhibit Glycoprotein and HIV Integrase for HIV-1 Infection - Drug Profile
Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection - Drug Profile
Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 - Drug Profile
Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection - Drug Profile
Small Molecules to Inhibit HIV-1 RT for HIV-1 Infection - Drug Profile
Small Molecules to Inhibit Nef for HIV-1 Infections - Drug Profile
Small Molecules to Inhibit Nuclear Export for Viral Infections and Cancer - Drug Profile
Small Molecules to Inhibit p25 and gp120 for HIV-1 Infection - Drug Profile
Small Molecules to Inhibit Ribonuclease H for HIV-1 Infection - Drug Profile
Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile
Stem Cell Therapy for HIV-1 Infection and Melanoma - Drug Profile
SV6-B - Drug Profile
SV6-C - Drug Profile
SVC-2 - Drug Profile
SVH1-C - Drug Profile
SVH1-D - Drug Profile
Synthetic Peptide 2 for HIV-1 Infection - Drug Profile
Synthetic Peptide for HIV-1 Infection - Drug Profile
Synthetic Peptide for Oncology and Infectious Disease - Drug Profile
THV-01 - Drug Profile
TMC-310911 - Drug Profile
UB-421 - Drug Profile
VAC-3S - Drug Profile
Vacc-4x - Drug Profile
Vacc-C5 - Drug Profile
VIR-353 - Drug Profile
VIR-576 - Drug Profile
VRC-01 - Drug Profile
VRC-02 - Drug Profile
HIV-1 Infection - Recent Pipeline Updates
HIV-1 Infection - Dormant Projects
HIV-1 Infection - Discontinued Products
HIV-1 Infection - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for HIV-1 Infection, H1 2015
Number of Products under Development for HIV-1 Infection - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..4)
HIV-1 Infection - Pipeline by AlphaVax, Inc., H1 2015
HIV-1 Infection - Pipeline by AltraVax Inc., H1 2015
HIV-1 Infection - Pipeline by Aphios Corporation, H1 2015
HIV-1 Infection - Pipeline by Argos Therapeutics, Inc., H1 2015
HIV-1 Infection - Pipeline by Bionor Pharma ASA, H1 2015
HIV-1 Infection - Pipeline by Biosantech SA, H1 2015
HIV-1 Infection - Pipeline by Boehringer Ingelheim GmbH, H1 2015
HIV-1 Infection - Pipeline by Bristol-Myers Squibb Company, H1 2015
HIV-1 Infection - Pipeline by CompleGen, Inc., H1 2015
HIV-1 Infection - Pipeline by Critical Outcome Technologies Inc., H1 2015
HIV-1 Infection - Pipeline by CytoDyn Inc., H1 2015
HIV-1 Infection - Pipeline by Enzo Biochem, Inc., H1 2015
HIV-1 Infection - Pipeline by FIT Biotech Oy, H1 2015
HIV-1 Infection - Pipeline by GeneCure LLC, H1 2015
HIV-1 Infection - Pipeline by Gilead Sciences, Inc., H1 2015
HIV-1 Infection - Pipeline by GlaxoSmithKline plc, H1 2015
HIV-1 Infection - Pipeline by Heat Biologics, Inc., H1 2015
HIV-1 Infection - Pipeline by InnaVirVax SA, H1 2015
HIV-1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015
HIV-1 Infection - Pipeline by Johnson & Johnson, H1 2015
HIV-1 Infection - Pipeline by Merck & Co., Inc., H1 2015
HIV-1 Infection - Pipeline by Mymetics Corporation, H1 2015
HIV-1 Infection - Pipeline by Myrexis, Inc., H1 2015
HIV-1 Infection - Pipeline by Oncovir, Inc., H1 2015
HIV-1 Infection - Pipeline by OyaGen Inc., H1 2015
HIV-1 Infection - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015
HIV-1 Infection - Pipeline by Pfizer Inc., H1 2015
HIV-1 Infection - Pipeline by Pharis Biotec GmbH, H1 2015
HIV-1 Infection - Pipeline by Spider Biotech, H1 2015
HIV-1 Infection - Pipeline by TaiMed Biologics Inc., H1 2015
HIV-1 Infection - Pipeline by Takara Bio Inc., H1 2015
HIV-1 Infection - Pipeline by Theravectys S.A., H1 2015
HIV-1 Infection - Pipeline by Tobira Therapeutics, Inc., H1 2015
HIV-1 Infection - Pipeline by United Biomedical, Inc., H1 2015
HIV-1 Infection - Pipeline by Valens Therapeutics, Inc., H1 2015
HIV-1 Infection - Pipeline by Vichem Chemie Research Ltd., H1 2015
HIV-1 Infection - Pipeline by ViiV Healthcare Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
HIV-1 Infection Therapeutics - Recent Pipeline Updates, H1 2015
HIV-1 Infection - Dormant Projects, H1 2015
HIV-1 Infection - Dormant Projects (Contd..1), H1 2015
HIV-1 Infection - Dormant Projects (Contd..2), H1 2015
HIV-1 Infection - Dormant Projects (Contd..3), H1 2015
HIV-1 Infection - Dormant Projects (Contd..4), H1 2015
HIV-1 Infection - Dormant Projects (Contd..5), H1 2015
HIV-1 Infection - Dormant Projects (Contd..6), H1 2015
HIV-1 Infection - Dormant Projects (Contd..7), H1 2015
HIV-1 Infection - Dormant Projects (Contd..8), H1 2015
HIV-1 Infection - Dormant Projects (Contd..9), H1 2015
HIV-1 Infection - Discontinued Products, H1 2015
HIV-1 Infection - Discontinued Products (Contd..1), H1 2015

List of Figures
Number of Products under Development for HIV-1 Infection, H1 2015
Number of Products under Development for HIV-1 Infection - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- AlphaVax, Inc.
- AltraVax Inc.
- Aphios Corporation
- Argos Therapeutics, Inc.
- Bionor Pharma ASA
- Biosantech SA
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- CompleGen, Inc.
- Critical Outcome Technologies Inc.
- CytoDyn Inc.
- Enzo Biochem, Inc.
- FIT Biotech Oy
- GeneCure LLC
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Heat Biologics, Inc.
- InnaVirVax SA
- Inovio Pharmaceuticals, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Mymetics Corporation
- Myrexis, Inc.
- Oncovir, Inc.
- OyaGen Inc.
- Peregrine Pharmaceuticals, Inc.
- Pfizer Inc.
- Pharis Biotec GmbH
- Spider Biotech
- TaiMed Biologics Inc.
- Takara Bio Inc.
- Theravectys S.A.
- Tobira Therapeutics, Inc.
- United Biomedical, Inc.
- Valens Therapeutics, Inc.
- Vichem Chemie Research Ltd.
- ViiV Healthcare Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.